Document is current
Any future updates will be listed below
-
Authors
Shen, Sherry https://orcid.org/0000-0001-9566-2864
Salehi, Erica https://orcid.org/0000-0003-1081-2216
White, Charlie
Chen, Yuan
Iyengar, Neil M. https://orcid.org/0000-0002-9773-5235
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Conquer Cancer Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 2 January 2024
Accepted: 14 June 2024
First Online: 29 June 2024
Competing interests
: The authors declare no competing interests. S.S. has received honoraria from MJH Life Sciences and receives research funding (to institution) from Merck and Sermonix Pharmaceuticals. N.M.I. receives consultant fees from Novartis, Pfizer, Seattle Genetics, Astra Zeneca, Gilead, Genentech/Roche, BD Life Sciences, TerSera Therapeutics, and research funding (to institution) from Novartis and SynDevRx.
